Article: Fluzone

A 5cc vial of Fluzone

Fluzone is the commercial name of an influenza virus vaccine, distributed by sanofi pasteur, USA. It is a split-virus vaccine, which is produced by chemical disruption of the influenza virus. Therefore, it is incapable of causing influenza per se.

As approved by the US Food and Drug Administration (FDA), Fluzone is a preservative-free vaccine administered in a single dose by intramuscular injection. It is presented as a 0.25 ml syringes for pediatric use and 0.5 ml syringes for adults and children. Vials must be stored under temperatures from 2 to 8 degrees Celsius and are inactivated by freezing. Fluzone was approved in April 2002 by the FDA. It is recommended for vaccination against the following type A and B influenza viruses and has been optimized for the 2004-2005 season.

• Type A: New Caledonia 20/99
• Type A: Wyoming 03/2003
• Type B: Jiangsu 10/2003

Fluzone is thimerosal-free.

The optimal vaccination period with Fluzone in the Northern hemisphere is October through November, because influenza activity usually begins in November or December, peaking in late December, and is strongly recommended for people 6 months of age or older. The use of Fluzone in infants less than 6 months of age is not recommended. Immunization with Fluzone may not protect 100% of susceptible individuals.

Adverse effects

• Mild soreness, local pain and swelling at the local of the injection
• In small children and in people with no previous exposure to a flu vaccine, episodes of fever, malaise, myalgia (muscle pain)
• In people who are sensitive to egg protein, allergic reactions may ensue, suchas hives, angioedema, asthma and anaphylaxis

See also

• Vaccine
• Vaccination
• Flu vaccine
• Influenza
• Public health